Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Clinical tip: use a separate syringe per peptide
Head-to-Head Comparison: Key Metrics Semaglutide: MW 4113.58 Da | Selective GLP-1 RA | Injectable (weekly) or oral (daily with SNAC) | Mean weight loss 14.9% (STEP 1) | FDA-approved 2021 (obesity) Tirzepatide: MW ~4813.45 Da | Dual GLP-1/GIP | Injectable (weekly) | Mean weight loss 22.5% (SURMOUNT-1) | FDA-approved 2023 (obesity) Retatrutide: MW ~4500 Da | Triple GLP-1/GIP/Glucagon | Injectable (weekly) | Mean weight loss 28.7% (TRIUMPH-4 Phase 3) | Phase 3 as of 2026 Orforglipron: MW 541.65 Da | Selective GLP-1 (non-peptide) | Oral (daily, no food restriction) | Mean weight loss ~14.7% (Phase 3) | FDA-approved April 2026 Receptor Selectivity and Mechanism Differences The four compounds represent a spectrum from single-target to multi-target pharmacology
In cities like Jaipur, where pollution, sun exposure, and lifestyle factors contribute to dull and pigmented skin, this treatment is increasingly in demand
What research says it may help with, and how it works in the body
This treatment-focused routine provides a targeted daily serum, a nourishing moisturising step and an intensive weekly hydration treatment
US$ 22.08
US$ 24.75
US$ 24.89
US$ 28.55
US$ 23.26
US$ 22.25
US$ 24.08
US$ 26.87
US$ 24.28
